License: Creative Commons Attribution 4.0 PDF - Published Version (3MB) |
- URN to cite this document:
- urn:nbn:de:bvb:355-epub-576824
- DOI to cite this document:
- 10.5283/epub.57682
Abstract
Cancer therapies with anthracyclines have been shown to induce cardiovascular complications. The aims of this study were to establish an in vitro induced pluripotent stem cell model (iPSC) of anthracycline-induced cardiotoxicity (ACT) from patients with an aggressive form of B-cell lymphoma and to examine whether doxorubicin (DOX)-treated ACT-iPSC cardiomyocytes (CM) can recapitulate the clinical ...
Owner only: item control page